Abstract:Background: Developing guidelines for the diagnosis and treatment of common cancers in China based on the evidence-based practice, the availability of diagnosis and treatment products, and the up-to-date advances in precision medicine is one of the basic tasks of the Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Committee. Methods: Protocols with high evidence level and good availability are used as the Level I recommendations; protocols with relatively high evidence level but slightly lower expert consensus or with poor availability are used as the Level II recommendations; and protocols that are clinically applicable but with low evidence level are regarded as the Level III recommendations. Based on the findings of clinical research at home and abroad and the opinions of CSCO BC experts, the CSCO BC guidelines determine the levels of recommendations for clinical application. Results: For human epidermal growth factor receptor 2 (HER2)-positive breast cancer, a combination of trastuzumab and pertuzumab regimen were recommended as Level I recommendation for neoadjuvant and first line metastatic breast cancer. Pyrotinib is also recommended as Level I recommendation in first line and second line therapy according to the latest studies conducted in China. Antibody drug conjugates was also recommended for patients with trastuzumab progression. For triple negative breast cancer, immunotherapy in early and metastatic breast cancer was highlighted and listed as new chapters in this version of guideline. For hormone receptor (HR)-positive breast cancer, cyclin dependent kinase 4/6 (CDK4/6) was recommended in different stages, especially in adjuvant therapy. There was also a new chapter for HER2-low breast cancer stratified by HR status. Conclusions: We firmly believe that evidence-based, availability-concerned, and consensus-based guidelines will be more feasible for clinical practice in China and in other countries with similar situations.

Guidelines on the diagnosis and treatment of breast cancer (2011 edition).

Updated Understanding on the National Comprehensive Cancer Network Guidelines (version 1. 2017) for Diagnosis and Treatment of Pancreatic Adenocarcinoma

Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)

Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)

Interpretation of Specification for Breast Cancer Screening, Early Diagnosis, and Treatment Management in Chinese Women

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

[Guidelines for clinical diagnosis and treatment of advanced triple negative breast cancer in China（2024 edition）]

Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)

Guideline of traditional chinese medicine diagnosis and treatment for breast cancer patients with emotional disorders (2023)

Further discussion on several concerns with diagnosis and treatment of early breast cancer

Guidelines for the Diagnosis and Treatment of Pancreatic Cancer in China (2021)

Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024

Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

Updates and interpretations of the National Comprehensive Cancer Network guidelines for breast cancer (Version 1, 2016)

National Consensus in China on Diagnosis and Treatment of Patients with Advanced Breast Cancer.

Interpretation of“guideline and standard for the diagnosis and treatment of breast cancer by Chinese ;Anti-Cancer Association (2015 edition)”:surgical section

Interpretation on hot topics of the 16th St.Gallen International Breast Cancer Conference

Clinical Practice Guidelines in Breast Cancer by Chinese Anti-Cancer Association (2015 version):interpretation of updates in terms of systemic treatment

Expert Consensus on Diagnosis, Treatment and Fertility Management of Young Breast Cancer Patients

National Guidelines for Diagnosis and Treatment of Colorectal Cancer 2020 in China (english Version)

Breast cancer: an up‐to‐date review and future perspectives